BioIndustry Association appoints new board of directors
This article was originally published in Scrip
Executive Summary
The BioIndustry Association (BIA) has appointed five new members to its board of directors: Dr John Brown, chairman of BTG and CXR Biosciences; Paul Drohan, general manager and vice-president of Genzyme UK and Ireland; Steven Harris, CEO of Circassia; Dr Ed Hodgkin, CEO of Biotica Technology; and Dr Sam Williams, CEO of Modern Biosciences. The BIA, which encourages and promotes the bioscience sector within the UK economy, also re-elected Kate Bingham, managing partner at SV Life Sciences; Tim Edwards, president and CEO of Cellzome; Dr Jeremy Haigh, vice-president and international chief operating officer, R&D, at Amgen; Geoff Newman, co-founder and managing director of Interea International; Ian Nicholson, CEO of Chroma Therapeutics; and Peter Nolan, executive director and senior vice-president of commercial development at Oxford BioMedica. All board members will serve from January 1st onwards.
You may also be interested in...
How to leverage India: Five up-and-coming domestic players
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
Active Biotech appoints CSO
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed appoints new chief commercial officer
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).